SCHOTT Pharma, an innovator in pharmaceutical drug containment solutions and delivery systems, revealed plans to establish its newest site in Wilson, North Carolina. The investment, supported by USD 21 million in state and local incentive awards, marks a significant expansion of SCHOTT Group's footprint in the United States, a pivotal market in its growth strategy.

The upcoming facility will be the first of its kind in the US, dedicated to manufacturing prefillable polymer syringes essential for the deep-cold storage and transportation of mRNA medications. Additionally, the site will have the capacity to produce glass prefillable syringes for GLP-1 therapies, addressing critical medical needs such as diabetes and obesity treatment. The project is set to create 401 jobs in the region, with a total investment of USD 371 million. Groundbreaking is anticipated by the end of 2024, with operations slated to commence in 2027.

This expansion aims to support the US supply chain for in-demand syringes, vital for administering life-saving injectable medicines, vaccines, and other applications. SCHOTT Pharma envisions tripling its contribution of glass and polymer syringes to the US market by 2030, thus ensuring quicker order fulfillment, reduced transportation costs, and enhanced pandemic preparedness.

Andreas Reisse, CEO of SCHOTT Pharma, emphasized the significance of local production, stating, "As drug manufacturers develop and expand the use of mRNA, GLP-1, and other biologic therapies, SCHOTT Pharma will be able to fill those orders quickly and efficiently here in the US"

Christopher Cassidy, President of SCHOTT North America, highlighted Wilson County's appeal, citing its skilled workforce and proximity to the Research Triangle area as key factors in the site selection process.

North Carolina Senator Buck Newton praised the investment, attributing it to the state's pro-growth policies and investments in biologics training facilities. He anticipates the venture to bolster the local economy and foster long-term success for SCHOTT Pharma in Wilson.

For over 20 years, SCHOTT Pharma has been a reliable partner in the pharmaceutical industry, manufacturing vials at its Lebanon, PA facility. The decision to expand in Wilson underscores the company's commitment to serving the US market and pursuing growth opportunities.

The project's location is contingent upon final real estate negotiations. SCHOTT Pharma collaborated with various organizations throughout the endeavor, including the North Carolina Department of Commerce, the Economic Development Partnership of North Carolina, and academic institutions such as the North Carolina Biotechnology Center and the Biomanufacturing Training and Education Center at North Carolina State University.